Neurotransmetteurs SRL
Neurotransmetteurs reported total assets of 58,639 € at the end of the 2025 financial year (annual accounts filed with the NBB on 24 Aug 2026).
The score of Neurotransmetteurs shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +15 % Total assets -13 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Neurotransmetteurs's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Aug 2026
- Year ended 31 Dec 2024filed on 05 Aug 2025
- Year ended 31 Dec 2023filed on 14 Aug 2024
- Year ended 31 Dec 2022filed on 03 Aug 2023
- Year ended 31 Dec 2021filed on 24 Aug 2022
Neurotransmetteurs's financial analysis
- Solvency72.1%sector median: 34.3%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Neurotransmetteurs
Neurotransmetteurs's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0721.658.026
- VAT number
- BE0721658026
- Peppol
- Registered · 0208:0721658026 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 27 Feb 2019
- Registered office
- 1370 Jodoigne
- Latest accounts
- 2025 · filed on 24 Aug 2026
- Activity
- Organisation of conventions and trade shows (NACE 82300)
Neurotransmetteurs (SRL) has been based in Jodoigne since 2019, active in: organisation of conventions and trade shows. For 2025, it reports a net profit of 16,846 € and equity of 42,294 €; its revenue is not published. Its solvency stands at 72.1%, above the median of its sector (34.3%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Neurotransmetteurs
Companies in the same business, of comparable size and area, outside its group.
- PerioEducQui Organisation of conventions and trade shows Leuven · balance sheet 48,021 €
- Scivias Business and other management consultancy activities Watermael-Boitsfort · balance sheet 41,306 €
- Les Originaux Organisation of conventions and trade shows Ottignies-Louvain-la-Neuve · balance sheet 41,782 €
- Vanderveken Medical Communication Organisation of conventions and trade shows Jodoigne · balance sheet 94,421 €
- "Lotte Smets" Business and other management consultancy activities Antwerp · balance sheet 36,634 €
- Corlyra Business and other management consultancy activities Woluwe-Saint-Pierre · balance sheet 37,539 €
- Himmc Organisation of conventions and trade shows Perwez · balance sheet 102,799 €
- Cofibri Organisation of conventions and trade shows Chaumont-Gistoux · balance sheet 119,783 €
Frequently asked questions about Neurotransmetteurs
What is the revenue of Neurotransmetteurs?
Neurotransmetteurs files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Neurotransmetteurs?
In Belgium, the VAT number is the company number prefixed with BE: BE0721658026 for Neurotransmetteurs, if the company is VAT-registered. Its company number (CBE) is 0721.658.026.
Where is the registered office of Neurotransmetteurs?
According to the CBE register, the registered office of Neurotransmetteurs is in 1370 Jodoigne.
What is the equity of Neurotransmetteurs?
At the close of the 2025 financial year, the equity of Neurotransmetteurs amounts to 42,294 €, a solvency of 72.1% of total assets.
Who manages Neurotransmetteurs?
The register lists 1 active mandates at Neurotransmetteurs. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Neurotransmetteurs
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →